101 related articles for article (PubMed ID: 12175536)
1. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma.
Jeng YM; Hsu HC
Cancer Lett; 2002 Jul; 181(2):205-8. PubMed ID: 12175536
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Kang CS; Kim KM; Jang JJ; Nam SW; Lee JY; Yoo NJ
Oncogene; 2001 Jan; 20(3):399-403. PubMed ID: 11313970
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Jang JJ; Han JY; Lee JY; Yoo NJ
Cancer Res; 1999 Nov; 59(22):5683-6. PubMed ID: 10582684
[TBL] [Abstract][Full Text] [Related]
4. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.
Adams J; Cuthbert-Heavens D; Bass S; Knowles MA
Cancer Lett; 2005 Apr; 220(2):137-44. PubMed ID: 15766588
[TBL] [Abstract][Full Text] [Related]
5. Rare loss-of-function mutation of a death receptor gene in head and neck cancer.
Pai SI; Wu GS; Ozören N; Wu L; Jen J; Sidransky D; El-Deiry WS
Cancer Res; 1998 Aug; 58(16):3513-8. PubMed ID: 9721851
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis and mRNA expression of trail-receptors in human breast cancer.
Seitz S; Wassmuth P; Fischer J; Nothnagel A; Jandrig B; Schlag PM; Scherneck S
Int J Cancer; 2002 Nov; 102(2):117-28. PubMed ID: 12385006
[TBL] [Abstract][Full Text] [Related]
7. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.
Shin MS; Kim HS; Lee SH; Park WS; Kim SY; Park JY; Lee JH; Lee SK; Lee SN; Jung SS; Han JY; Kim H; Lee JY; Yoo NJ
Cancer Res; 2001 Jul; 61(13):4942-6. PubMed ID: 11431320
[TBL] [Abstract][Full Text] [Related]
8. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
Rubio-Moscardo F; Blesa D; Mestre C; Siebert R; Balasas T; Benito A; Rosenwald A; Climent J; Martinez JI; Schilhabel M; Karran EL; Gesk S; Esteller M; deLeeuw R; Staudt LM; Fernandez-Luna JL; Pinkel D; Dyer MJ; Martinez-Climent JA
Blood; 2005 Nov; 106(9):3214-22. PubMed ID: 16051735
[TBL] [Abstract][Full Text] [Related]
9. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma.
Chen XP; He SQ; Wang HP; Zhao YZ; Zhang WG
World J Gastroenterol; 2003 Nov; 9(11):2433-40. PubMed ID: 14606071
[TBL] [Abstract][Full Text] [Related]
10. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1.
Higuchi H; Grambihler A; Canbay A; Bronk SF; Gores GJ
J Biol Chem; 2004 Jan; 279(1):51-60. PubMed ID: 14561739
[TBL] [Abstract][Full Text] [Related]
11. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.
Wolf S; Mertens D; Pscherer A; Schroeter P; Winkler D; Gröne HJ; Hofele C; Hemminki K; Kumar R; Steineck G; Döhner H; Stilgenbauer S; Lichter P
Int J Cancer; 2006 Apr; 118(7):1831-5. PubMed ID: 16217763
[TBL] [Abstract][Full Text] [Related]
12. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas.
Arai T; Akiyama Y; Okabe S; Saito K; Iwai T; Yuasa Y
Cancer Lett; 1998 Nov; 133(2):197-204. PubMed ID: 10072170
[TBL] [Abstract][Full Text] [Related]
13. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
[TBL] [Abstract][Full Text] [Related]
14. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
15. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance.
Ozören N; Fisher MJ; Kim K; Liu CX; Genin A; Shifman Y; Dicker DT; Spinner NB; Lisitsyn NA; El-Deiry WS
Int J Oncol; 2000 May; 16(5):917-25. PubMed ID: 10762627
[TBL] [Abstract][Full Text] [Related]
16. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma.
Shiraki K; Yamanaka T; Inoue H; Kawakita T; Enokimura N; Okano H; Sugimoto K; Murata K; Nakano T
Int J Oncol; 2005 May; 26(5):1273-81. PubMed ID: 15809718
[TBL] [Abstract][Full Text] [Related]
17. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.
Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A
Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890
[TBL] [Abstract][Full Text] [Related]
18. MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4.
Xu C; Shi L; Chen W; Fang P; Li J; Jin L; Pan Z; Pan C
Oncotarget; 2017 Jun; 8(26):41921-41931. PubMed ID: 28410209
[TBL] [Abstract][Full Text] [Related]
19. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
